Cherrier, M. M.
Cross, D. J.
Higano, C. S.
Minoshima, S.
Article History
Received: 30 October 2017
Revised: 13 December 2017
Accepted: 18 December 2017
First Online: 27 April 2018
Compliance with ethical standards
:
: C.S.H. has acted in a consulting/advisory role for Dendreon, Bayer, Medivation, Ferring, Orion, Emergent Biosolutions, MorphoSys, Churchill Pharmaceuticals, Astellas Pharma, Clovis Oncology, Parexel, Asana Biosciences, Endocyte, Blue Earth Diagnostics; has received research funding for projects (unrelated to this project) from Algeta/Bayer, Aragon Pharmaceuticals, AstraZeneca, Dendreon, Genentech, Medivation, Sanofi, Emergent Biosolutions, Bayer, Pfizer; has received travel accomodations or expenses from Bayer, Dendreon, Astellas Pharma, Emergent Biosolutions, Churchill Pharmaceuticals, Clovis Oncology, Blue Earth Diagnostics, Asana Biosciences, Emergent Biosolutions, Endocyte, Ferring, Genentech, Orion Pharma GmbH, Menarini, Myriad Genetics. The remaining authors declare that they have no conflict of interest.